|
(V1726)
|
Impact of inflammatory markers and post-treatment platelet aggregation on mortality and the incidence of myocardial infarction and stent thrombosis in patients undergoing coronary intervention
|
|
T. Geisler, K. A. L. Müller, M. Herkommer, P. Htun, C. S. Zürn, S. Fateh-Moghadam, A. May, M. Gawaz (Tübingen)
|
|
(V1727)
|
Risiko von Patienten mit Bare-Metal-Stents nach dem Absetzen von Clopidogrel
|
|
W. Hochholzer, D. Trenk, C. M. Valina, C. Stratz, H.-P. Bestehorn, H. J. Büttner, F.-J. Neumann (Bad Krozingen)
|
|
(V1728)
|
Klinisches Management von Patienten mit verminderter Thrombozyten-aggregationshemmung unter Thienopyridinen mittels Thrombozytenfunktionstest und individueller Anpassung der Medikation
|
|
M. Zechmeister, J. Nagel, C. G. Schuhmann, M. Spannagl, H.-Y. Sohn, V. Klauss, F. Krötz (München)
|
|
(V1729)
|
Right Ventricular Dysfunction leeds to insufficient response to Clopidogrel – a new Risk Factor of Clopidogrel Resistance ?
|
|
K. Ibrahim, S. Kolschmann, C. Wunderlich, M. Christoph, R. H. Strasser (Dresden)
|
|
(V1730)
|
Increased Fractalkine Levels are Associated with Impaired Clopidogrel Responsiveness in Patients with Coronary Artery Disease
|
|
U. Flierl, J. Bauersachs, A. Schäfer (Würzburg)
|
|
(V1731)
|
Impact of Concomitant Treatment with Proton Pump Inhibitors and Clopidogrel on Stent Thrombosis and Mortality in Patients after Coronary Stent Implantation
|
|
I. Tentzeris, R. Jarai, S. Farhan, I. Brosovic, P. Smetana, A. Geppert, J. Wojta, J. Siller-Matula, K. Huber (Wien, AT)
|